INDICATION AND LIMITATIONS OF USE

Vectibix® in combination with sotorasib is indicated for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy....READ MORE

Limitations of Use: Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. Vectibix® is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown.

About KRAS G12C
Prevalence
KRASG12C inhibition
Efficacy
CodeBreaK 100
Safety
Dosing
Dosing
Dose modification
Coadministration
Testing
Why to test
How to test
Support & Resources
Amgen® SupportPlus
Dispensing resources
Patient resources
HOME

KRAS G12C in mCRC

~ 4% of patients with mCRC have the actionable KRAS G12C mutation1

Prevalence of mutations and aberrations in molecular biomarkers in mCRC1,*

Data on RAS status are from a retrospective pooled analysis of 5 published, randomized, controlled trials of patients treated with Vectibix®, chemotherapy, other targeted therapies, or best supportive care. Three Phase 3 studies included mCRC patients. One Phase 1B/2 study and one Phase 2 study included mCRC patients with wild type KRAS exon 2 tumor status only1.

Data on BRAF and HER2 status are from a literature review of modalities targeting the EGFR pathway through diagnostics and inhibitors, as well as clinical resistance mechanisms2

Data on microsatellite and NTRK status are from a review of predictive biomarkers in mCRC and associated targeted therapies3

Approximately 2/3 of mCRC patients may be clinically eligible
for a biomarker-driven FDA-approved therapy1-3

*Percentages are approximations. Overlapping aberrations may be observed in some tumors.1-3

†Exon 2 mutations included KRAS G12A, G12S, G12R, G12D, G12V, and G13D. Exon 3 mutations included KRAS Q61E, Q61H, Q61K, Q61L, and Q61R. Exon 4 mutations included KRAS A146P, A146T, A146V, and K117N. NRAS mutations included G12A, G12C, G12D, G12F, G12N, G12R, G12S, G12V, G12W, G13C, G13D, G13E, G13R, G13V, Q61E, Q61H, Q61K, Q61L, Q61R, K117N, A146P, A146T, and A146V.1

‡This includes samples where information for specific exons and codons were missing while still having overall RAS mutational status.1

§Prevalence was derived from the median value of the estimated range of BRAF V600E occurring in 8%–10% of CRC.2

A real-world study showed patients who have the KRAS G12C mutation had shorter OS compared with those with other KRAS mutations or WT-RAS or WT-BRAF mCRC4

Median OS among patients in the KRAS G12C, KRAS non-G12C, and overall mCRC cohorts4,**

KRAS G12C may be associated with a worse prognosis in mCRC5

Data are from a retrospective study of adults with mCRC diagnosed between January 1, 2011 and March 31, 2020 in a US-based clinical-genomic database, categorized by mutation status and characterized by clinicopathologic characteristics, treatment patterns, and outcomes using descriptive analysis. Patients were followed for at least 6 months following diagnosis of mCRC4

**Based on patients receiving 1L treatment. Other real-world studies of treatment outcomes in KRAS G12C–mutated mCRC have reported mixed results, with some describing poorer prognosis, while others describing no difference.4,5

1L, first line; BRAF, v-Raf murine sarcoma viral oncogene homolog B; CI, confidence interval; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; mCRC, metastatic colorectal cancer; MSI, microsatellite instability; MT, mutant type; NRAS, neuroblastoma rat sarcoma viral oncogene homolog; NTRK, neurotrophic-tropomyosin receptor kinase; OS, overall survival; RAS, rat sarcoma; WT, wild type.

Inhibition of
KRAS G12C–mutated
mCRC

Combining LUMAKRAS® + Vectibix® in the treatment of KRAS G12C–mutated mCRC

Learn more about the LUMAKRAS® + Vectibix® mechanism of action6,7

Mechanism of action representations are for illustrative purposes only and not intended to imply any clinical significance.

  • LUMAKRAS® + Vectibix® provide dual inhibition of KRASG12C protein and WT-RAS pathway
  • LUMAKRAS® locks KRASG12C in an inactive state; however, this leads to reactivation of EGFR and WT-RAS pathways
  • Vectibix® inhibits EGFR and blocks tumor growth signaling that bypasses inactivated KRASG12C

Mechanism of action representations are for illustrative purposes only and not intended to imply any clinical significance.

LUMAKRAS® + Vectibix® are not chemotherapies or TKIs. They inhibit KRASG12C and EGFR, respectively, to inhibit tumor growth in mCRC6,7

EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; mCRC, metastatic colorectal cancer; RAS, rat sarcoma; TKI, tyrosine kinase inhibitor; WT, wild type.

LUMAKRAS® IMPORTANT SAFETY INFORMATION

Hepatotoxicity

  • LUMAKRAS® can cause hepatotoxicity and increased ALT or AST which may lead to drug-induced liver injury and hepatitis.
  • In the pooled safety population of NSCLC patients who received single agent LUMAKRAS® 960 mg hepatotoxicity occurred in 27% of patients, of which 16% were Grade ≥ 3. Among patients with hepatotoxicity who required dosage modifications, 64% required treatment with corticosteroids.
  • In this pooled safety population of NSCLC patients who received single agent LUMAKRAS® 960 mg, 17% of patients who received LUMAKRAS® had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); of which 9% were Grade ≥ 3. The median time to first onset of increased ALT/AST was 6.3 weeks (range: 0.4 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 9% of patients treated with LUMAKRAS®. LUMAKRAS® was permanently discontinued due to increased ALT/AST in 2.7% of patients. Drug-induced liver injury occurred in 1.6% (all grades) including 1.3% (Grade ≥ 3).
  • In this pooled safety population of NSCLC patients who received single agent LUMAKRAS® 960 mg, a total of 40% patients with recent (≤ 3 months) immunotherapy prior to starting LUMAKRAS® had an event of hepatotoxicity. An event of hepatotoxicity was observed in 18% of patients who started LUMAKRAS® more than 3 months after last dose of immunotherapy and in 17% of those who never received immunotherapy. Regardless of time from prior immunotherapy, 94% of hepatotoxicity events improved or resolved with dosage modification of LUMAKRAS®, with or without corticosteroid treatment.
  • Monitor liver function tests (ALT, AST, alkaline phosphatase, and total bilirubin) prior to the start of LUMAKRAS®, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, reduce the dose or permanently discontinue LUMAKRAS® based on severity of the adverse reaction. Consider administering systemic corticosteroids for the management of hepatotoxicity.

Interstitial Lung Disease (ILD)/Pneumonitis

  • LUMAKRAS® can cause ILD/pneumonitis that can be fatal.
  • In the pooled safety population of NSCLC patients who received single agent LUMAKRAS® 960 mg ILD/pneumonitis occurred in 2.2% of patients, of which 1.1% were Grade ≥ 3, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 8.6 weeks (range: 2.1 to 36.7 weeks). LUMAKRAS® was permanently discontinued due to ILD/pneumonitis in 1.3% of LUMAKRAS®-treated patients. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS® in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS® if no other potential causes of ILD/pneumonitis are identified.

Most Common Adverse Reactions

  • The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Drug Interactions

  • Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over‑the‑counter drugs, vitamins, dietary and herbal products.
  • Inform patients to avoid proton pump inhibitors and H2 receptor antagonists while taking LUMAKRAS®.
  • If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS® 4 hours before or 10 hours after a locally acting antacid.

Please see full LUMAKRAS® Prescribing Information.

VECTIBIX® IMPORTANT SAFETY INFORMATION

BOXED WARNING: DERMATOLOGIC TOXICITY

Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix® monotherapy [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

  • Vectibix® can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, acneiform dermatitis, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures.
  • Among 229 patients who received Vectibix® as monotherapy, dermatologic toxicity occurred in 90% including Grade 3 (15%). Among 585 patients who received Vectibix® in combination with FOLFOX, dermatologic toxicity occurred in 96% including Grade 4 (1%) and Grade 3 (32%). In 126 patients receiving Vectibix® in combination with sotorasib across clinical studies, dermatologic toxicities occurred in 94%, including Grade 3 (16%) of patients.
  • Monitor patients who develop dermatologic or soft tissue toxicities while receiving Vectibix® for the development of inflammatory or infectious sequelae. Life-threatening and fatal infectious complications including necrotizing fasciitis, abscesses, and sepsis have been observed in patients treated with Vectibix®. Life-threatening and fatal bullous mucocutaneous disease with blisters, erosions, and skin sloughing has also been observed in patients treated with Vectibix®. It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis). Withhold or discontinue Vectibix® for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Dose modifications for Vectibix® concerning dermatologic toxicity are provided [see Dosage and Administration (2.3)].
  • Vectibix® monotherapy or in combination with oxaliplatin-based chemotherapy is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS and hereafter is referred to as “RAS.”
  • Retrospective subset analyses across several randomized clinical trials were conducted to investigate the role of RAS mutations on the clinical effects of anti-EGFR-directed monoclonal antibodies (panitumumab or cetuximab). Anti-EGFR antibodies in patients with tumors containing RAS mutations resulted in exposing those patients to anti-EGFR related adverse reactions without clinical benefit from these agents. Additionally, in Study 20050203, 272 patients with RAS-mutant mCRC tumors received Vectibix® in combination with FOLFOX and 276 patients received FOLFOX alone. In an exploratory subgroup analysis, OS was shorter (HR = 1.21, 95% CI: 1.01-1.45) in patients with RAS-mutant mCRC who received Vectibix® and FOLFOX versus FOLFOX alone.
  • Vectibix® can cause progressively decreasing serum magnesium levels leading to severe (Grade 3 or 4) hypomagnesemia. Among 229 patients who received Vectibix® as monotherapy, hypomagnesemia occurred in 38% including Grade 4 (1.3%) and Grade 3 (2.6%). Among 585 patients who received Vectibix® in combination with FOLFOX, hypomagnesemia occurred in 51% including Grade 4 (5%) and Grade 3 (6%). In 126 patients receiving Vectibix® in combination with sotorasib across clinical studies, decreased magnesium occurred in 69%, including Grade 4 (2.4%) and Grade 3 (14%).
  • Monitor patients for hypomagnesemia and hypocalcemia prior to initiating Vectibix® treatment, periodically during Vectibix® treatment, and for up to 8 weeks after the completion of treatment. Other electrolyte disturbances, including hypokalemia, have also been observed. Replete magnesium and other electrolytes as appropriate.
  • In Study 20020408, 4% of patients experienced infusion reactions and 1% of patients experienced severe infusion reactions (NCI-CTC Grade 3-4). Infusion reactions, manifesting as fever, chills, dyspnea, bronchospasm, and hypotension, can occur following Vectibix® administration. Fatal infusion reactions occurred in postmarketing experience. Terminate the infusion for severe infusion reactions.
  • Severe diarrhea and dehydration, leading to acute renal failure and other complications, have been observed in patients treated with Vectibix®. Among 229 patients who received Vectibix® as monotherapy, acute renal failure occurred in 2% including Grades 3 or 4 (2%). Among 585 patients who received Vectibix® in combination with FOLFOX, acute renal failure occurred in 2% including Grade 3 or 4 (2%). In 126 patients receiving Vectibix® in combination with sotorasib across clinical studies, acute renal failure occurred in 3.2%, including Grade 3 (0.8%). Monitor patients for diarrhea and dehydration, provide supportive care (including anti-emetic or anti-diarrheal therapy) as needed, and withhold Vectibix® if necessary.
  • Fatal and nonfatal cases of interstitial lung disease (ILD) (1%) and pulmonary fibrosis have been observed in patients treated with Vectibix®. Pulmonary fibrosis occurred in less than 1% (2/1467) of patients enrolled in clinical studies of Vectibix®. Grade 1 ILD/pneumonitis occurred in 0.8% (1/126) of patients enrolled in clinical studies of Vectibix® in combination with sotorasib. In the event of acute onset or worsening of pulmonary symptoms interrupt Vectibix® therapy. Discontinue Vectibix® therapy if ILD is confirmed.
  • In patients with a history of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis, the benefits of therapy with Vectibix® versus the risk of pulmonary complications must be carefully considered.
  • Exposure to sunlight can exacerbate dermatologic toxicity. Advise patients to wear sunscreen and hats and limit sun exposure while receiving Vectibix®.
  • Serious cases of keratitis, ulcerative keratitis, and corneal perforation have occurred with Vectibix® use. Among 585 patients who received Vectibix® in combination with FOLFOX, keratitis occurred in 0.3%. In 126 patients receiving Vectibix® in combination with sotorasib across clinical studies, keratitis occurred in 1.6%, ulcerative keratitis occurred in 0.8%, and vernal keratoconjunctivitis in 0.8% (all were Grade 1-2). Monitor for evidence of keratitis, ulcerative keratitis, or corneal perforation. Interrupt or discontinue Vectibix® therapy for acute or worsening keratitis, ulcerative keratitis, or corneal perforation.
  • In an interim analysis of an open-label, multicenter, randomized clinical trial in the first-line setting in patients with mCRC, the addition of Vectibix® to the combination of bevacizumab and chemotherapy resulted in decreased OS and increased incidence of NCI-CTC Grade 3-5 (87% vs 72%) adverse reactions. NCI-CTC Grade 3-4 adverse reactions occurring at a higher rate in Vectibix®-treated patients included rash/acneiform dermatitis (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%), primarily occurring in patients with diarrhea, hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs <1%), and hypomagnesemia (4% vs 0). NCI-CTC Grade 3-5 pulmonary embolism occurred at a higher rate in Vectibix®-treated patients (7% vs 3%) and included fatal events in three (< 1%) Vectibix®-treated patients.
  • As a result of the toxicities experienced, patients randomized to Vectibix®, bevacizumab, and chemotherapy received a lower mean relative dose intensity of each chemotherapeutic agent (oxaliplatin, irinotecan, bolus 5-FU, and/or infusional 5-FU) over the first 24 weeks on study compared with those randomized to bevacizumab and chemotherapy.
  • Based on data from animal studies and its mechanism of action, Vectibix® can cause fetal harm when administered to a pregnant woman. When given during organogenesis, panitumumab administration resulted in embryolethality in cynomolgus monkeys at exposures approximately 1.25 to 5 times the recommended human dose. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment, and for at least 2 months after the last dose of Vectibix®.
  • In monotherapy, the most commonly reported adverse reactions (≥ 20%) in patients with Vectibix® were skin rash with variable presentations, paronychia, fatigue, nausea, and diarrhea.
  • The most commonly reported adverse reactions (≥ 20%) with Vectibix® + FOLFOX were diarrhea, stomatitis, mucosal inflammation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin. Serious adverse reactions (≥ 2% difference between treatment arms) were diarrhea and dehydration.
  • The most common adverse reactions (≥ 20%) in patients receiving Vectibix® in combination with sotorasib 960 mg were rash, dry skin, diarrhea, stomatitis, fatigue and musculoskeletal pain.

Please see full Prescribing Information for Vectibix®,
including BOXED WARNING.

INDICATION

Vectibix® in combination with sotorasib is indicated for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

LIMITATIONS OF USE

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC.

Vectibix® is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown.

References: 1. The Galien Foundation. https://www.prnewswire.com/news-releases/the-galien-foundation-honors-2022-prix-galien-award-recipients-301662219.html. Accessed August 12, 2024. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Vectibix® (panitumumab) prescribing information, Amgen. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer v.5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer v.4.2024. © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. Fakih MG, et al. N Engl J Med. 2023;389:2125-2139. 7. The Galien Foundation. https://www.galienfoundation.org/what-you-must-know. Accessed September 19, 2024. 8. The Galien Foundation. https://candidates.prix-galien-usa.com/submissions/eligibility. Accessed September 19, 2024.

References: 1. Peeters M, et al. Eur J Cancer. 2015;51:1704-1713. 2. Doleschal B, et al. Front Oncol. 2022;12:1-16. 3. Cohen R, et al. Cancers. 2020;12:2350. 4. Fakih M, et al. Oncologist. 2022;27:663-674. 5. Lee J, et al. NPJ Precis Oncol. 2022;6:91. 6. LUMAKRAS® (sotorasib) prescribing information, Amgen. 7. Vectibix® (panitumumab) prescribing information, Amgen.

References: 1. LUMAKRAS® (sotorasib) prescribing information, Amgen. 2. Vectibix® (panitumumab) prescribing information, Amgen. 3. Pietrantonio F, et al. Presented at: The Meeting of the European Society for Medical Oncology; October 20–23, 2023; Madrid, Spain. Abstract LBA10. 4. Fakih M, et al. N Engl J Med. 2023;389:2125–2139. 5. Data on File, Amgen; [KRAS Trials sites]. 6. Fakih M, et al. Presented at: 115th Annual Meeting of the American Association for Cancer Research; May 31–June 4, 2024; Chicago, IL. Abstract LBA3510. 7. Data on File, Amgen; [CodeBreaK 300 PROs Data]. 8. Data on File, Amgen; [Clinical Efficacy Response Rates].

References: 1. LUMAKRAS® (sotorasib) prescribing information, Amgen. 2. Vectibix® (panitumumab) prescribing information, Amgen. 3. Fakih M, et al. N Engl J Med. 2023;389:2125-2139. 4. Data on file, Amgen; [CodeBreaK 300 Safety]. 5. Gorji M, et al. Asia-Pac J Clin Oncol. 2023;18:526-539. 6. Lacouture M, et al. Support Care Cancer. 2011;19:1079-1095. 7. Kobayashi Y, et al. Future Oncol. 2015;11:617-627.

References: 1. LUMAKRAS® (sotorasib) prescribing information, Amgen. 2. Vectibix® (panitumumab) prescribing information, Amgen.

References: 1. Taieb J, et al. Drugs. 2019;79:1375-1394. 2. Patel J, et al. J Pers Med. 2019;9:3. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer v.5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Roche Diagnostics. https://diagnostics.roche.com/us/en/products/params/cobas-kras-mutation-test.html. Accessed June 9, 2023. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer v.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. LUMAKRAS® (sotorasib) prescribing information, Amgen. 7. Vectibix® (panitumumab) prescribing information, Amgen. 8. Sepulveda A, et al. J Mol Diagn. 2017;19:187-225.

Reference: 1. Data on file, Amgen; [Amgen SupportPlus Patients and HCPs].

Adverse Reactions in mCRC Patients Receiving Combination Therapy

The most common adverse reactions (≥ 20%) in clinical trials of LUMAKRAS® in combination with Vectibix® are rash including dermatitis acneiform, hypomagnesemia, dry skin, diarrhea, fatigue, and stomatitis. The most common laboratory abnormalities (≥ 25%) were decreased magnesium, decreased calcium, decreased hemoglobin, increased alkaline phosphatase, increased aspartate aminotransferase, increased alanine aminotransferase, decreased potassium, decreased lymphocytes, decreased white blood cells, increased urine protein and increased creatinine kinase.

INDICATION

LUMAKRAS®, in combination with Vectibix®, is indicated for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

References: 1. LUMAKRAS® (sotorasib) prescribing information, Amgen. 2. Vectibix® (panitumumab) prescribing information, Amgen. 3. Fakih MG, et al. N Engl J Med 2023;389:2125-2139. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer v.5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer v.4.2024. © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed August 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LUMAKRAS® IMPORTANT SAFETY INFORMATION

Hepatotoxicity

  • LUMAKRAS® can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.

VECTIBIX® IMPORTANT SAFETY INFORMATION

BOXED WARNING: DERMATOLOGIC TOXICITY

Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving

References: 1. Peeters M, et al. Eur J Cancer. 2015;51:1704-1713. 2. Doleschal B, et al. Front Oncol. 2022;12:1-16. 3. Cohen R, et al. Cancers. 2020;12:2350. 4. Fakih M, et al. Oncologist. 2022;27:663-674. 5. Lee J, et al. NPJ Precis Oncol. 2022;6:91. 6. LUMAKRAS® (sotorasib) prescribing information, Amgen. 7. Vectibix® (panitumumab) prescribing information, Amgen.